Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
venBio Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
venBio Partners

venBio Partners

Operating

venBio: A leading life sciences investment firm, funding promising startups to late-stage ventures.

Location
San Francisco, CA, US
Founded
2009
Firm
Compare
Portfolio
Employees
Website

Investments

Attovia Therapeutics
Attovia Therapeutics

Total Raised

$60M

Rounds

1

Series A$60MJune 2023
Entact Bio
Entact Bio

Total Raised

$120.9M

Rounds

2

Series A$81MDecember 2022
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Series C$107MJanuary 2021
Immpact Bio
Immpact Bio

Total Raised

$129M

Rounds

2

Series B$111MJanuary 2022
Ceptur Therapeutics
Ceptur Therapeutics

Total Raised

$81.2M

Rounds

2

Series A$75MJanuary 2022
HistoWiz
HistoWiz

Total Raised

$36.8M

Rounds

6

Series A$32.3MOctober 2021
Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Series C$45MOctober 2019
Attralus
Attralus

Total Raised

$141.2M

Rounds

3

Series B$116MSeptember 2021
Series A$25MSeptember 2020
Neurogastrx
Neurogastrx

Total Raised

$105M

Rounds

2

Series B$60MAugust 2021
Series A$45MJanuary 2018
Artiva Biotherapeutics
Artiva Biotherapeutics

Total Raised

$198M

Rounds

2

Series B$120MFebruary 2021
Series A$78MJune 2020
Tallac Therapeutics
Tallac Therapeutics

Total Raised

$88.2M

Rounds

3

Series A$62MDecember 2020
Stargazer Pharmaceuticals
Stargazer Pharmaceuticals

Total Raised

$94.2M

Rounds

3

Series A$57MNovember 2020
NFlection Therapeutics
NFlection Therapeutics

Total Raised

$41.4M

Rounds

4

Series A$20MJune 2020
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals

Total Raised

$37.8M

Rounds

6

Series A$37MOctober 2019
Arrakis Therapeutics
Arrakis Therapeutics

Total Raised

$113M

Rounds

2

Series B$75MApril 2019
Precision BioSciences
Precision BioSciences
Public

Total Raised

$225.2M

Rounds

6

Series B$110MJune 2018
Harmony Biosciences
Harmony Biosciences
Public

Total Raised

$1.2B

Rounds

8

Series Unknown$270MOctober 2017
Apellis Pharmaceuticals
Apellis Pharmaceuticals
Public

Total Raised

$168.5M

Rounds

11

Series E$60MAugust 2017
Series D$47MFebruary 2016
Vyne Therapeutics
Vyne Therapeutics
Public

Total Raised

$297.8M

Rounds

7

Series C$50.5MJuly 2017